ArticleEvidence-based complementary and alternative medicine : eCAM2022
Efficacy of Ambroxol Hydrochloride Combined with Amoxicillin Potassium Clavulanate Combination on Children with Bronchopneumonia and Its Impact on the Level of Inflammatory Factors.
Article in Evidence-based complementary and alternative medicine : eCAM, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Exploring the Effects of Prone Position Ventilation Combined with Drug on Clinical Outcomes in Neonates with ARDS: A Single-Center Retrospective Cohort Study.Therapeutics and clinical risk management · 2026Article
- Ambroxol hydrochloride spray (Luo Runchang®) in the treatment of acute respiratory infectious diseases: a prospective, multicenter, open label, randomized controlled study.Frontiers in pediatrics · 2024Article
- Retracted: Efficacy of Ambroxol Hydrochloride Combined with Amoxicillin Potassium Clavulanate Combination on Children with Bronchopneumonia and Its Impact on the Level of Inflammatory Factors.Evidence-based complementary and alternative medicine : eCAM · 2023Article
Corrections and comments
- Retraction · 2023-06-21Concerns/Issues about Data · Concerns/Issues about Referencing/Attributions · Concerns/Issues about Peer Review · Investigation by Journal/Publisher · Investigation by Third Party · Unreliable Results and/or Conclusions · · See also: https://pubpeer.com/publications/11206E475F8D9ACE0C796812293F05
- Retracted
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: The goal of the present study was to examine the effect of ambroxol hydrochloride combined with amoxicillin potassium clavulanate combination on children with bronchopneumonia and its influence on the level of inflammatory factors. Methods: From January 2018 to June 2019, 100 children with bronchopneumonia admitted to the Pediatric Department of Nanjing Pukou District Hospital of Traditional Chinese Medicine were enrolled as the study subjects. The children were assigned either to an observation group or a control group in a ratio of 1:1 using the random alphabet method. The observation group was treated with ambroxol hydrochloride plus amoxicillin potassium clavulanate combination, and the control group was treated with amoxicillin potassium clavulanate combination. The therapeutic efficiency and serum white blood cells (WBC), C-reactive protein (CRP), interleukin-6 (IL-6), and tumor necrosis factor-a (TNF- Results: Regarding the effective rate of treatment, the observation group (94%) was observed to be notably higher as compared to the control group (84%). The levels of WBC, CRP, IL-6, and TNF- Conclusion: The findings of the present study demonstrate that ambroxol hydrochloride combined with amoxicillin potassium clavulanate combination might be a reliable approach for the treatment of bronchopneumonia in children. It can synergistically relieve inflammation with high safety profiles.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.